Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -98.15% is 28% below its 5-year average of -76.51%, around the middle of its 5-year range (-128.66%–-43.88%).
8.13% above its 12-month average of -106.83%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -16.79%.
RETURN ON ASSETS (ROA)
-98.15%
RETURN ON ASSETS (ROA) AVG TTM
-106.83%
RETURN ON ASSETS (ROA) AVG 3Y
-87.42%
RETURN ON ASSETS (ROA) AVG 5Y
-76.51%
RETURN ON ASSETS (ROA) AVG 10Y
-68.94%
RETURN ON ASSETS (ROA) AVG 15Y
-56.43%
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+8.13%
CURRENT VS 3Y AVG
-12.28%
CURRENT VS 5Y AVG
-28.28%
CURRENT VS 10Y AVG
-42.37%
CURRENT VS 15Y AVG
-73.93%
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-32.27%
median of 862 covered companies
CURRENT VS SECTOR MEDIAN
-204.20%
vs the sector median at left
Verastem, Inc.
Market Cap
$681.02M
Return on Assets (ROA)
-98.15%
TTM Avg
-106.83%
3Y Avg
-87.42%
5Y Avg
-76.51%
Market Cap
$681.27M
Return on Assets (ROA)
-49.24%
TTM Avg
-70.53%
3Y Avg
-58.08%
5Y Avg
-52.49%
Market Cap
$685.49M
Return on Assets (ROA)
-38.01%
TTM Avg
-251.96%
3Y Avg
-211.47%
5Y Avg
-174.45%
Market Cap
$673.41M
Return on Assets (ROA)
2.22%
TTM Avg
15.13%
3Y Avg
10.21%
5Y Avg
1.65%
Market Cap
$691.79M
Return on Assets (ROA)
-42.04%
TTM Avg
-29.58%
3Y Avg
-35.66%
5Y Avg
-28.85%
Market Cap
$693.19M
Return on Assets (ROA)
-103.29%
TTM Avg
-79.28%
3Y Avg
-61.36%
5Y Avg
-60.54%
Market Cap
$693.61M
Return on Assets (ROA)
-36.26%
TTM Avg
-29.77%
3Y Avg
-47.75%
5Y Avg
-50.63%
Market Cap
$694.79M
Return on Assets (ROA)
-18.03%
TTM Avg
-7.81%
3Y Avg
-4.40%
5Y Avg
-1.35%
Market Cap
$666.95M
Return on Assets (ROA)
-70.67%
TTM Avg
-51.05%
3Y Avg
-54.02%
5Y Avg
-55.25%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Verastem, Inc. (VSTM) | $681.02M | -98.15% | -106.83% | -87.42% | -76.51% |
| Solid Biosciences Inc. (SLDB)vs › | $681.27M | -49.24% | -70.53% | -58.08% | -52.49% |
| Anteris Technologies Global Corp. (AVR)vs › | $685.49M | -38.01% | -251.96% | -211.47% | -174.45% |
| MiMedx Group, Inc. (MDXG)vs › | $673.41M | 2.22% | 15.13% | 10.21% | 1.65% |
| Olema Pharmaceuticals, Inc. (OLMA)vs › | $691.79M | -42.04% | -29.58% | -35.66% | -28.85% |
| Faeth Therapeutics, Inc. (FTH)vs › | $693.19M | -103.29% | -79.28% | -61.36% | -60.54% |
| Wave Life Sciences Ltd. (WVE)vs › | $693.61M | -36.26% | -29.77% | -47.75% | -50.63% |
| Cytek Biosciences, Inc. (CTKB)vs › | $694.79M | -18.03% | -7.81% | -4.40% | -1.35% |
| Helus Pharma Inc. (HELP)vs › | $666.95M | -70.67% | -51.05% | -54.02% | -55.25% |
| Annexon, Inc. (ANNX)vs › | $660.29M | -82.36% | -56.97% | -52.21% | -45.34% |
ROA
-98.2%
ROE
-405.5%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -85.00% |
| 2024-12-31 | -128.66% |
| 2023-12-31 | -58.35% |
| 2022-12-31 | -77.66% |
| 2021-12-31 | -65.52% |
| 2020-12-31 | -43.88% |
| 2019-12-31 | -102.87% |
| 2018-12-31 | -26.13% |
| 2017-12-31 | -75.51% |
| 2016-12-31 | -43.57% |
| 2015-12-31 | -51.17% |
| 2014-12-31 | -54.10% |
| 2013-12-31 | -32.89% |
| 2012-12-31 | -34.42% |
| 2011-12-31 | -23.18% |
| 2010-12-31 | 0.00% |
